Leucid Bio Unveils ‘Parallel CAR-T’ Platform Targeting Solid Tumors
Based On Veteran Researcher’s Innovation
Executive Summary
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.
You may also be interested in...
Single Patient Safety Concern Hits Allogene’s Off-The-Shelf CAR-T
Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.
Immunocore Could Gain Green Light For First T-Cell Receptor Drug In Early 2022
The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.